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Abstract
Background: Two biomarkers, the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR),
have been shown to be indicative of systemic inflammation and predictive of mortality in general population. We
aimed to assess the association of NLR and PLR, with risk of death in HIV-infected subjects when also taking
account of HIV-related factors.
Methods: We conducted a multicenter Italian cohort study from 2000 to 2012 including HIV-infected subjects naïve
at antiretroviral treatment.
The associations of NLR and PLR with all-cause mortality were tested by univariate and multivariate analyses using
both time independent and dependent Cox proportional hazard models. We also fitted models with a cubic-spline
for PLR and NLR to evaluate the possible non-linear relationship between biomarkers values and risk of death.
Results: Eight-thousand and two hundred thirty patients (73.1% males) with a mean age of 38.4 years (SD 10.1) were
enrolled. During a median follow-up of 3.9 years, 539 patients died. PLR < 100 and≥ 200, as compared to PLR of 100–200,
and NLR≥ 2, as compared to < 2, were associated with risk of death at both univariate and multivariate analyses. Using
multivariate models with restricted cubic-splines, we found a linear relationship of increasing risk of death with increasing
values for NRL over 1.1, and an U-shape curve for PLR, with higher mortality risk for values higher or lower than 120.
Conclusions: Our data suggest that NLR and PLR can reflect the severity of the underlying systemic disturbance of the
inflammatory process and coagulation leading to augmented mortality in HIV positive subjects.
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Background
High circulating levels of markers of inflammation and
coagulation, most notably C-Reactive protein (CRP),
IL-6, and D-dimer, have been demonstrated to be pre-
dictors of incidence and mortality for cardiovascular
(CV) and non-CV diseases in healthy subjects [1–3].
Inflammation systemic markers have been also associ-
ated with an increased risk of death from any cause in
an apparently healthy adult population [4, 5].
HIV-infected people even with long-term, effective
antiretroviral therapy have persistent, low grade inflam-
mation and immune activation [6, 7], and elevated levels
of inflammation biomarkers (eg. IL-6, TNF, D-dimer,
fibrinogen and C-reactive protein) have been shown to
be strong predictors of non-AIDS events and all-cause
mortality, when also controlling for CD4 count and HIV
plasma replication [7–11].
Recently, two biomarkers derived from common blood
parameters, the neutrophil to lymphocyte ratio (NLR) and
platelet to lymphocyte ratio (PLR), have been shown to be
indicative of systemic inflammation and predictive of
morbidity and mortality for both CV and non-CV diseases,
mainly cancer, in HIV-negative subjects [12–14].
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Different cut-off values of NLR and PLR have been used
in clinical studies carried out so far, depending on subjects
investigated (people with solid cancers, hematological ma-
lignancies, sepsis, cardiovascular diseases, diabetes, or the
general population), types of end-point (incidence and/or
prevalence of diseases, response to therapy, reactivation of
diseases after treatment or death). Most studies have been
performed on prognostic role of these biomarkers in pa-
tients with cancer [13, 15]. On the other hand, few studies
have been carried out on these biomarkers in the general
population. In the USA general population examination
survey (NAHNES), the NLR average was 2.15, ranging
from 2.06 to 2.44 according to ethnicity, sex, education,
age, BMI, smoking, alcohol drinking, diabetes or heart
conditions [16]. Also many chronic conditions are known
to increase the body inflammatory status [17].
Two previous studies carried out by us showed that
NLR and PLR were associated with risk of death in a large
cohort of HIV-infected patients with solid cancers or
lymphoma [18, 19]. However, no study has been carried
out on the role of these factors as predictors of all-cause
mortality in all patients with HIV infection, so far, to our
knowledge.
The aim of our study was to assess the association of
PLR and NLR with risk of death in HIV-infected sub-
jects when also taking account of HIV-related factors.
Methods
Study population
The Italian MASTER cohort is a hospital-based multicen-
ter, open, dynamic cohort established in the mid-1990s,
with retrospective patients’ enrolment from 1986 to 1997
and prospective recruitment subsequently. Enrollment in
MASTER is independent of the HIV disease stage, degree
of immunosuppression or use of antiretroviral therapy.
Clinical data are recorded for each patient in an electronic
database every 3/4 months and data checking are
performed at a central level every 6 months [20]. For the
present study, we included patients enrolled in MASTER
cohort from January 2000 to December 2012 before start-
ing their first combined antiretroviral therapy (cART).
Patients were subsequently follow-up during the study
period, independently of undergoing cART and of time of
starting therapy.
We collected data on gender, age, date of enrolment,
country of origin, HIV exposure risk, viral hepatitis C or
B co-infection from the MASTER electronic database.
The following parameters, measured at enrolment and
each year, were also retrieved: AIDS event and cancer
occurrence, HIV-RNA, CD4 cell count, CD8 cell count,
neutrophil, lymphocyte and platelet counts. Late presen-
tation refers to people diagnosed with HIV with a CD4
cell count below 350/mm3 or with an AIDS defining
event regardless of the CD4 cell count in the 6 months
following HIV diagnosis. Late presentation with HIV ad-
vanced disease refers to persons diagnosed with HIV
with a CD4 cell count below 200/mm3 or with an AIDS
defining event, regardless of CD4 cell count in the
6 months following HIV diagnosis [21].
Vital status and date of death were ascertained through
clinical charts, and through a record-linkage with Local
Health Authority mortality registers in about one third of
patients.
The study was conducted in accordance with the
guidelines of the Declaration of Helsinki and the princi-
ples of Good Clinical Practice. The study protocol was
approved by the local ethics committees. Written in-
formed consent was obtained by all patients enrolled.
Exposure factors and outcome
The exposure factors evaluated in our study were PLR
and NLR. After evaluating the variability in literature and
exploring the dose-response relationship between values
of these biomarkers and risk of death by spline curves in
our cohort (Fig. 1), we defined three categories of bio-
markers values on the basis of the shape of the spline
curves, according to the following cut-offs: <100, 100–200
and ≥200 for PLR, and <2, 2–4 and ≥4 for NLR.
The primary outcome of this study was all-causes
mortality.
Statistical analysis
Follow-up was determined from date of enrollment in
the cohort to 31st December 2012, or last follow-up
visit, or death, whichever occurred first. Mortality rates
were standardized for gender and age using the direct
method with the European population as the standard
and truncated at 65 years. Rates were expressed per
1000 person-years (PYs).
The associations of NLR and PLR with all-cause mortal-
ity were tested by univariate and multivariate analyses
using both time independent and time dependent Cox
proportional hazard models, which provided estimates of
hazards ratios (HRs), their 95% confidence intervals (CIs),
and p-values according to Wald test. In time dependent
models, the study period was divided into 1 year intervals,
and gender, age at enrolment, intravenous drug use as risk
factors, hepatitis C or B virus co-infection and year of
enrolment were included as fixed covariates, whereas
AIDS events, CD4 cell count and cART were included as
time-dependent covariates. On the contrary, in time inde-
pendent models, we included all the covariates as detected
at enrolment.
In order to compare the goodness of fit of the model with
and without the inflammatory variables, we used the likeli-
hood ratio test. Various sensitivity analyses were also
performed using multivariate time dependent models in
which: i) CD4 cell count was replaced with CD4/CD8 ratio,
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ii) cART was replaced with HIV-RNA as a dichotomous
variable (positive vs negative), iii) cancer occurrence was
included as a time dependent covariate, iv) inverse prob-
ability weighted technique was applied in order to adjust
for losses to follow-up, v) the analysis was restricted to
patients who started cART, vi) the analysis was stratified by
presence of HBV (defined as presence of HBsAg) or HCV
(defined as HCV ab positive) coinfection.
To evaluate whether the associations of PLR and NLR with
risk of death were not linear, we also fitted time dependent
Cox models with a cubic-spline for PLR and NLR, respect-
ively [22] . We used the Akaike’s information criterion (AIC)
[23] to assess fitting of models with linear and non-linear
terms, and to choose the number of spline knots.
The proportional hazards assumption was investigated for
each single covariate and globally by analyzing Schoenfeld
residuals. We first produced the graphical plots and then
carried out formal statistical tests of their independence over
the rank transformation of time, but no departures from this
assumption were found.
The study had more than 90% power to detect a hazard
ratio of death of two for being in the highest vs the lowest
category of NLR value, with a two sided test and a level of
alpha of 0.05, having a ratio of about 10:1 of patients in
the lowest and the highest categories of NLR, respectively.
All statistical tests were two-sided, assumed a level of
significance of 0.05 and were performed using Stata soft-
ware version 12.0 (StataCorp, College Station, TX, USA).
Results
Of the 23,964 subjects enrolled in the MASTER cohort
up to 2012, 13,579 were excluded because had been en-
rolled before 2000 and 1975 were excluded because
non-naive at antiretroviral treatment at enrollment, leav-
ing a total of 8230 subjects.
Table 1 describes the baseline characteristics of the total
8230 HIV-positive subjects (73.1% males, mean age ±
standard deviation (SD) =38.4 ± 10.1). 7877 (95.7%) sub-
jects started a cART during the follow-up with a mean
time to ART start of 325.2 days. The mean (SD) CD4 cell
count and HIV-RNA serum level were 395.5 (277.6) cells/
mm3 and 4.6 (1.0) log10 copies/ml, respectively. Less than
half of them had more advanced HIV infection at
enrolment, with 40.7% having advanced late presentation
(CD4 cell count < 200 or an AIDS-defining condition in
the 6 months following HIV diagnosis). CD4/CD8 ratio
mean (SD) was 0.4 (0.3) and about 40% of patients had
CD4/CD8 ratio less than 0.3. Less than half had PLR
between 100 and 200 and most patients had NLR less
than 2 (71.8%). The NLR and PLR baseline values
increased significantly with age and were significantly
higher in females than males (data not shown in table).
Additional file 1: Figure S1 showed the PLR and NLR
distribution at enrolment: 25th percentile, median and 75th
percentile were 83, 114 and 163 for PLR, and 1,1.4 and 2.1
for NLR. When considering the variations of NLR and PLR
values during follow-up, we observed that NLR increased
whereas PLR decreased overtime, mainly as a consequence
of an increase of total lymphocyte count combined with a
decrease of platelet count, independently of the presence of
HCV co-infection (Additional file 2: Figure S2).
During a median follow-up of 3.9 years (total person
years = 38257.54), 539 (6.6%) patients died. Gender- and
age-adjusted mortality rates decreased from 26.3/1000 PYs
(19.3–33.2 CI 95%) in 2000–2002 to 14.9 (11.0–18.8) in
2003–2006, 9.9 (7.2–12.5) in 2007–2009 and 9.5 (7.3–
Fig. 1 Risk of death (Hazard Ratio) according to distribution of PLR and NLR. a PLR was modeled by cubic spline (solid line) with four knots in Cox
regression model adjusted for gender, age, intravenous drug use, AIDS event, CD4 cell count and antiretroviral therapy. The reference value is
120. b NLR was modeled by cubic spline (solid line) with four knots in Cox regression model adjusted for gender, age, intravenous drug use, AIDS
event, CD4 cell count and antiretroviral therapy. The reference value is 1.1. The 95% confidence limits are shown as dashed lines. Vertical axes have
a logarithmic scale. Abbreviations: PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio
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11.7) in 2010–2012 (test for linear trend: p < 0.001) (data
not shown).
The cumulative probability of loss to follow-up at
3 years was 20.4% (19.5–21.3%).
The prognostic role of PLR and NLR using time
independent and time dependent univariate Cox regres-
sion models is shown in Table 2. PLR less than 100 and
higher than 200, as compared to PLR between 100 and
200, was associated with a higher risk of death; similarly,
subjects with NLR between 2 and 4 and higher than 4,
as compared to less than 2, had higher risk of death in
both models. These results were confirmed using both
using time independent and time dependent multivariate
models, including gender, age and HIV related-variables
as shown in Table 3. The likelihood ratio tests for the
global fit of the model, before and after addition of
inflammatory variables to the full model, were significant
for both NLR and PLR (p < 0.001).
Similar results were obtained using time dependent
multivariate models with the following changes, with re-
spect to the main analysis: i) replacing CD4 cell count
with CD4/CD8 ratio, ii) replacing antiretroviral therapy
with HIV-RNA positivity, iii) including cancer occurrence
as covariate, and iv) weighting model for losses to follow-
up (data not shown), v) limiting the analysis to patients
who started a cART, vi) stratified the analysis for presence
of HBV or HCV coinfection. PLR and NLR were also
evaluated in multivariate time-dependent Cox regression
models with restricted cubic-splines for these variables
(Fig. 1), we also separated the analysis for coinfection
status (Fig. 2). The risk of death increased significantly
with increasing NLR over 1.1 (NLR ≥ 1.1 vs NLR < 1.1: RR =
1.80, CI 95% 1.29–2.514), whereas it was U shaped for PLR,
with the lowest value at 120 and increasing risk
before and after this value in whole cohort and in
subjects with and without HBV/HCV coinfection.
Discussion
This is the first study showing that increased values of
NLR and PLR, two simple and reliable markers of
inflammation, are associated with all-cause mortality in
HIV-infected people, independently of CD4 level and
other well-established HIV mortality risk factors, to our
knowledge. Both NLR and PLR values measured at
baseline and those measured during follow-up, analyzed
as time-dependent variables, were predictive of death in
these subjects.
These findings are in agreement with those from studies
performed in non-HIV-infected patients, showing that in-
flammation is predictor of total mortality. In HIV infected
people, CD4 count is considered to be the most important
predictive factor of clinical outcome. CD4 count, however,
was not associated with biomarkers of immune-activation
or inflammation in HIV subjects under successful cART




Gender Male 6013 (73.1)





Mean (SD) 38.4 (10.1)
Country of origin Italy 6539 (80.7)
Others 1561 (19.3)




IDU Yes 4516 (35.8)
HBV/HCV co-infection Yes 2430 (29.5)






Mean (SD) 395.5 (277.6)
CD4/CD8 ratio <0.3 2733 (40.3)
0.3–0.45 1356 (20.0)
≥0.45 2689 (39.7)
Mean (SD) 0.4 (0.3)
HIV-RNA log10 Mean (SD) 4.6 (1.0)
Late presentation Yes 4516 (58.6)
Advanced late presentation Yes 3135 (40.7)
Lymphocytes Mean (SD) 1962.4 (896.5)
Platelets Mean (SD) 220351.6 (80150.0)
Neutrophils Mean (SD) 2910.9 (1456.2)
PLR <100 2675 (39.1)
100–200 3132 (45.7)
≥200 1043 (15.2)
Mean (SD) 139.1 (100.8)
NLR <2 3826 (71.8)
2.4 1200 (22.5)
≥4 305 (5.7)
Mean (SD) 1.8 (1.5)
Late presentation refers to persons diagnosed with HIV with a CD4 cell count
below 350/mm3 or with an AIDS defining event regardless of the CD4 cell
count in the 6 months following HIV diagnosis. Late presentation with HIV
advanced disease refers to persons diagnosed with HIV with a CD4 cell count
below 200/mm3 or with an AIDS defining event, regardless of CD4 cell count
in the 6 months following HIV
Abbreviations: SD standard deviation, IDU intravenous drug use, HBV Hepatitis
B viruses, HCV Hepatitis C viruses, PLR platelet to lymphocyte ratio, NLR
neutrophil to lymphocyte ratio
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[21, 24]. In fact, recently it has been shown the potential
clinical role of CD4/CD8 ratio as prognostic factor for ser-
ious non-AIDS events and death even in patients who
were virologically suppressed after several years of anti-
retroviral therapy and CD4 recovery [25].
The NLR is believed to reflect the balance between in-
nate (neutrophils) and adaptive (lymphocytes) immune
responses, and the PLR is related with both aggregation
and inflammation pathways. Theses markers have been
described as predictors of either incidence of, and mor-
tality for many diseases. Chronic low-grade inflamma-
tion measured by NLR has been found to be associated
with various diseases or syndromes such as hyperten-
sion, metabolic syndrome, and osteoporosis [12, 26–28].
Furthermore, NLR was a significant prognostic factor for
various diseases, including cardiovascular disease and
malignancy, systemic infection or inflammatory disor-
ders [12, 29]. Also PLR was associated with adverse
cardiovascular outcome and mortality in patients with
myocardial infarction [30] and with fatal outcome in
subjects with various malignancies [15, 16].
However, no definite cut-offs for defining “high” and
“low” values of NLR and PLR as predictors of disease inci-
dence and mortality have been established so far. For this
reason, we preferred to evaluate these biomarkers on the
basis of their distribution in HIV-infected patients, and
found a linear relationship of increasing risk of death with
increasing values for NRL over 1.1, but an U-shape curve
for PLR, with higher mortality risk for PLR values higher or
lower than 120. This last finding was unexpected as no
previous study found an increased risk of mortality for low
values of PLR. As PLR is computed as the platelet to lympho-
cyte ratio, high and low values of this biomarker may be a
consequence of thrombocytosis and thrombocytopenia,
respectively. Both these conditions may be related with an
increased risk of non-AIDS-defining events in HIV positive
subjects: thrombocytosis is a well-known risk factor for vas-
cular ischemic events, whereas thrombocytopenia has been
related to high plasma levels of inflammation biomarkers
such as IL-6 [31, 32], and to the risk of developing both
AIDS and non-AIDS-defining events, including cancer and
cardiovascular diseases [33, 34]. Accordingly, both low and
high platelet count have been associated with incidence of
both AIDS and non-AIDS-defining events, mainly cancer,
during HIV disease [35].
HIV infection produces by itself an activation of
inflammatory and coagulation pathways with elevated plasma
levels of markers of inflammation and coagulation, both con-
tributing to occurrence of serious non-AIDS events [36, 37]
and to all-cause mortality even in virologically suppressed
patients [9, 11]. Indeed, a recent analysis of the U.S. National
Health and Nutrition Examination Survey (NHANES) data
has demonstrated that a chronic, low-grade inflammation,
measured as white blood cell count (WBC), is a direct, age-
independent contributor to the disease burden in the general
population [38]. Bastard et al. [39] have described an inflam-
mation and immune activation status, measured with IL-6,
CPR, B-2 microglobuline, D-dimer, sCD14, independently of
HIV-related factors (current CD4 or CD8 values, CD4 nadir,
CD4/CD8, previous AIDS event, duration or type of ART) in
treated, virologically-controlled HIV-infected patients.
However, discordant results of the impact of different
regimens of ART on markers of inflammation have been
published [40, 41].
The strengths of this study include a large population
size and an unselected group of HIV-infected patients.
Some limitations also exist, which should be taken into
consideration when interpreting the results of this study.
First, this is a multi-center observational study and
therefore, although we evaluated also HIV-related fac-
tors, the potential remains for residual confounding.
Second, we had no data on the causes of death, therefore
we could not evaluate the associations of NLR and PLR
with specific causes or groups of causes of death.
Conclusions
Our data from a cohort of HIV-infected subjects suggest
that simple indicators of systemic inflammation, as NLR
and PLR, which have previously been demonstrated
effective as prognostic markers in many diseases, could
Table 2 Univariate Cox proportional regression models with death for all-causes as outcome
UnadjustedCox proportional models Unadjustedtime-dependent Cox proportional models
Variables Categories HR (95% CI) P value HR (95% CI) P value
PLR <100 1.38 (1.10–1.73) 0.006 1.21 (0.95–1.53) NS
100–200 Ref Ref
≥200 2.27 (1.77–2.92) <0.001 3.87 (2.97–5.05) <0.001
NLR <2 Ref Ref
2–4 1.54 (1.19–1.99) 0.001 2.21 (1.71–2.89) <0.001
≥4 3.27 (2.36–4.53) <0.001 8.06 (5.90–11.0) <0.001
Time-dependent Cox regression models, CD8 CD4 ratio, PLR, NLR were considered at enrolment and every year. The observational period were divided into
intervals of 1 year duration
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, PLR platelet to lymphocyte ratio, NLR neutrophil to lymphocyte ratio
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provide valuable prognostic information also in HIV
infected patients. A comparison of these findings with
other studies should be made with caution, due to
substantial differences of the distribution of these
biomarkers according to gender, age, ethnicity and
various conditions and diseases. Our data need further
validation and more studies are necessary to evaluate
whether these parameters can be useful as markers of
development or worsening of concomitant chronic
diseases, including cardiovascular disease, kidney dis-
ease, osteoporosis and cancer, thus leading to augmented
mortality in HIV patients.
Additional files
Additional file 1: Figure S1. Distribution of PLR and NLR at enrollment.
Abbreviations: PLR, platelet to lymphocyte ratio; NLR, neutrophil to
lymphocyte ratio. (TIF 220 kb)
Additional file 2: Figure S2. Variations of NLR and PLR values over
time, means, 95% confidence intervals and subjects at risk. Abbreviations:
PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LB,
lower bound; UB, upper bound. (TIF 160 kb)
Abbreviations
AIC: Akaike’s information criterion; cART: Combined antiretroviral therapy;
CI: Confidence interval; CRP: C-Reactive protein; CV: Cardiovascular;
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Survey; NLR: Neutrophil to lymphocyte ratio; PLR: Platelet to lymphocyte
ratio; PY: Person-year; WBC: White blood cell count
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